|
|
The information source for Canadian Life Science professionals in the San Francisco Bay Area and Silicon Valley
|
|
|
CELS is a not for profit association supporting the advancement of innovative Canadian Life Science companies in the San Francisco Bay Area and Silicon Valley through the power of Community and Connections.
|
|
|
|
|
As we conclude the Spring 2022 edition of the CELS Valley Ready (VR) program, we invite you to join our virtual Demo Day!
This is a great opportunity to view pitches from our 7 Canadian Life Science startups on
Thursday, September 8th,
9:00 - 10:30 am PST / 12:00 - 1:30 pm EST
To join us, please register here.
We are extremely thankful for all our speakers and mentors who have provided immense support to the Cohort of participating companies. |
|
|
Valley Ready Fall 2022 Applications Open! |
We're looking for Canada's most innovative Life Science companies to join us for the 5th edition of the Valley Ready Program. Full with curriculum-based activities, this combination of virtual and live sessions helps companies from Pre-Seed to Series A navigate the best of Silicon Valley. Read more here! Application deadline: September 7, 2022 |
|
|
|
|
|
|
Featuring Canadian Life Science companies in the Spring 2022 Cohort of the CELS Valley Ready (VR) program. For more info on the CELS VR program click here!
|
|
|
|
|
Inteligex is a Toronto-based biotechnology company with a vision to use cell-based therapies to restore function for those living with brain and spinal cord injuries (SCI). Recent ground-breaking scientific discoveries are being leveraged to bring to market the world’s first successful neural stem cell-based therapy to restore upper limb and bowel/bladder function in individuals living with SCIs. Inteligex’s therapies are based on over three decades of award-winning research conducted in Dr. Michael Fehlings’ lab at the University Health Network (Toronto, Canada). Read more here!
|
|
|
|
|
Hear our cohort company Allarta Life Science talk about their exciting research using a new cell-based therapy, which alleviates need for insulin injections and immune-suppressive drugs. Read here! |
|
|
|
|
|
|
September 7-9, 2022
Boston, MA |
The Annual Healthcare conference is back! For registration, please click here! For more information, please email. |
|
|
|
|
|
|
|
|
|
BMO Capital Markets Biopharma Virtual Spotlight Series: Gene Editing & Therapy
For more information, please email. |
|
|
|
|
|
|
|
|
|
Nov 14-16, 2022 San Francisco, CA |
|
|
A global Medical Device Conference encompassing an Innovation Summit Conference Series. For more information, click here. |
|
|
Hear from our exclusive legal partner, Torys LLP, on the top legal considerations for life science companies.
Licensing for Life Science Companies
In our latest Torys’ Tips, Cheryl Reicin and Adam Falconi share some key factors you should keep in mind when assessing if you should license your life science product. Read more here! |
|
|
|
|
The US healthcare environment is evolving and changing since the onset of COVID in early 2020 and Digital Health is an area of rapid change, particularly evident as we are now in the middle of 2022. Keeping on top of the market and the changes that are coming in terms of the economy and the investment landscape, it’s important to keep track of the opportunities and the threats that this sector is experiencing post-pandemic. Read more here! |
|
|
|
|
Congratulations to partner and chair of Torys' Life Sciences practice Cheryl Reicin on being shortlisted for the 2022 LMG Life Sciences Awards for U.S. Venture Capital Attorney of the Year—one of only five lawyers nominated in this category. This builds upon last year’s recognition by LMG Life Sciences where Cheryl Reicin was named Canadian Finance & Corporate Attorney of the Year.
Torys is also shortlisted for seven other categories by LMG Life Sciences. Read more here.
Winners will be announced on September 8. |
|
|
|
|
|
|
If you would like to contribute to the newsletter, provide feedback or seek CELS membership info please email us at info@cels-sfo.com
|
|
|
|
